Reviewer's report

Title: Cost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazine

Version: 2 Date: 5 March 2011

Reviewer: Peter Laszlo Lakatos

Reviewer's report:

The revised manuscript is improved. Limitations were mostly addressed adequately.

Minor comment;
Please revise the last statement in the results “In summary, the results from the analysis show that over a five year as well as a lifelong time horizon, Mezavant is less expensive and results in higher gains of QALYs compared with Asacol. The analysis and its results are reasonably robust as the PSA shows.”

In the present form this is conclusion to the discussion but not Results.

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

none